NCT05032820: Phase 2: MM CAR-T to Upgrade Response BMT CTN 1902
Updated: Feb 10
BMT CTN 1902
NCT05032820: Phase 2: MM CAR-T to Upgrade Response BMT CTN 1902
MM CAR-T to Upgrade Response BMT CTN 1902
This study is designed as a Phase II, multicenter, single arm trial to assess anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptor (CAR) T-cells (bb2121) to improve post autologous hematopoietic cell transplant (HCT) responses among patients with multiple myeloma (MM).
Sponsor
Marcelo Pasquini, MD
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Blood and Marrow Transplant Clinical Trials Network
National Cancer Institute (NCI)
National Marrow Donor Program
Celgene a wholly owned subsidiary of BMS
Information provided by (Responsible Party)
Marcelo Pasquini, MD, Medical College of Wisconsin
Multiple Locations
ClinicalTrials.gov Identifier: NCT02786511
Official Title: Phase II Multicenter Trial of Anti-BCMA CAR T-Cell Therapy for MM Patients With Sub-Optimal Response After Auto HCT and Maintenance Len. BMT CTN 1902
First Posted : September 2, 2021
Click here for details on ClinicalTrials.gov
Drug: Lenalidomide and bb2121
Locations
United States, California
United States, Florida
United States, Illinois
United States, Massachusetts
United States, New York
United States, North Carolina
United States, Pennsylvania
United States, Virginia
United States, Wisconsin